RESUMO
ABSTRACT Objective Micronutrient deficiencies are recognized as critical factors contributing to the global burden of disease. Phoenixin-14 and nesfatin-1 newly discovered neuropeptides which have been related to various physiological processes and potential therapeutic applications. This study was conducted to test whether circulating concentrations of nesfatin-1 and phoenixin-14 were altered in individuals with iron, vitamin B12, vitamin D and combined deficiencies. Method Our study group consists of 33 patients with iron deficiency, 30 patients with vitamin B12 deficiency, 33 patients with vitamin D deficiency, 32 patients with combined deficiency, 24 patients who received vitamin D supplementation and 32 control subjects. Serum nesfatin-1 and phoenixin-14 concentrations were determined measured by Enzyme-Linked ImmunoSorbent Assay method. Results Serum phoenixin-14 values were significantly lower in subjects with iron, vitamin B12, vitamin D and combined deficiency compared with the healthy group. After vitamin D supplementation, serum phoenixin-14 levels did not differ significantly with the healthy group. Serum nesfatin-1 concentrations were significantly lower in subjects with iron, vitamin B12 and combined deficiency compared with the healthy group. There was no significant difference in nesfatin-1 values between those with vitamin D deficiency, those taking vitamin D3 supplements and the healthy controls. Conclusion Significant differences in phoenixin-14 and nesfatin-1 levels between iron, vitamin D, vitamin B12 deficiency and the healthy control group supports that these molecules related to the pathogenesis of micronutrient deficiencies. Phoenixin-14 and nesfatin-1 may be considered potential biomarkers of micronutrient deficiencies.
RESUMO Objetivo As deficiências de micronutrientes são reconhecidas como fatores críticos que contribuem para a carga global de doenças. Neuropeptídeos recém-descobertos Phoenixin-14 e nesfatin-1 que foram relacionados a vários processos fisiológicos e potenciais aplicações terapêuticas. Este estudo foi realizado para testar se as concentrações circulantes de nesfatina-1 e fenixina-14 estevam alteradas em indivíduos com deficiência de ferro, vitamina B12, vitamina D e combinada. Método Nosso grupo de estudo consiste em 33 pacientes com deficiência de ferro, 30 pacientes com deficiência de vitamina B12, 33 pacientes com deficiência de vitamina D, 32 pacientes com deficiência combinada, 24 pacientes que receberam suplementação de vitamina D e 32 controles. As concentrações séricas de nesfatina-1 e fenixina-14 foram determinados pelo método Enzyme-Linked ImmunoSorbent Assay. Resultados Os valores séricos de fenixina-14 foram significativamente menores em pacientes com deficiência de ferro, vitamina B12, vitamina D e combinada em comparação com o grupo controle. Após a suplementação de vitamina D, os níveis séricos de fenixina-14 não diferiram significativamente com o grupo controle. Os valores séricos de nesfatina-1 foram significativamente menores em pacientes com deficiência de ferro, vitamina B12 e combinada em comparação com o grupo controle. Não houve diferença nos níveis de nesfatina-1 entre aqueles com deficiência de vitamina D, recebendo vitamina D3 ou aqueles controles saudáveis. Conclusão Nosso estudo observou diferenças significativas nas concentrações de fenixina-14 e nesfatina-1 entre ferro, vitamina D, deficiência de vitamina B12 e o grupo controle. A fenixina-14 e a nesfatina podem estar relacionadas à patogênese das deficiências de micronutrientes.
RESUMO
OBJECTIVE: Hypertension is a major modifiable risk factor for cardiovascular disease and premature death worldwide. Phoenixin is a newly identified neuropeptide with multiple bioactivity. However, there was no published data about phoenixin levels in hypertension. The aim of this study was to evaluate the relationship between phoenixin and hypertension. METHODS: This study was performed in 36 patients with hypertension and 36 healthy controls. Serum phoenixin-14 and phoenixin-20 levels were determined by Enzyme-Linked ImmunoSorbent Assay method. RESULTS: Serum phoenixin-14 and phoenixin-20 values were significantly lower in hypertension patients compared with the control group (p<0.001). The levels of phoenixin-14 were negatively correlated with weight (r=-0.376; p<0.005), body mass index (r=-0.407; p<0.001), systolic blood pressure (r=-0.586; p<0.001), and diastolic blood pressure (r=-0.319; p<0.01). There was a negative correlation between serum phoenixin-20 and weight (r=-0.378; p<0.005), body mass index (r=-0.383; p<0.005), systolic blood pressure (r=-0.551; p<0.001), and diastolic blood pressure (r=-0.306; p<0.01). We used receiver operating characteristic curve analyses to compare the diagnosis value of Phoenixin-14 and Phoenixin-20 levels in hypertensive patients. We found that Phoenixin-14 value is an area under the curve of 0.87 (cutoff value 404.7 ng/L, sensitivity 92%, specificity 72%) and Phoenixin-20 value is an area under the curve of 0.83 (cutoff value 209.9 ng/L, sensitivity 86%, specificity 75%). Phoenixin-14 did nearly show equally compared to phoenixin-20 in predicting hypertension. CONCLUSION: Serum phoenixin-14 and phoenixin-20 may be related to the pathogenesis of hypertension. Our findings indicated that serum phoenixin-14 and phoenixin-20 may serve as a novel biomarker for the diagnosis of hypertension.
Assuntos
Hipertensão , Biomarcadores , Pressão Sanguínea , Índice de Massa Corporal , Humanos , Fatores de RiscoRESUMO
SUMMARY OBJECTIVE: Hypertension is a major modifiable risk factor for cardiovascular disease and premature death worldwide. Phoenixin is a newly identified neuropeptide with multiple bioactivity. However, there was no published data about phoenixin levels in hypertension. The aim of this study was to evaluate the relationship between phoenixin and hypertension. METHODS: This study was performed in 36 patients with hypertension and 36 healthy controls. Serum phoenixin-14 and phoenixin-20 levels were determined by Enzyme-Linked ImmunoSorbent Assay method. RESULTS: Serum phoenixin-14 and phoenixin-20 values were significantly lower in hypertension patients compared with the control group (p<0.001). The levels of phoenixin-14 were negatively correlated with weight (r=-0.376; p<0.005), body mass index (r=-0.407; p<0.001), systolic blood pressure (r=-0.586; p<0.001), and diastolic blood pressure (r=-0.319; p<0.01). There was a negative correlation between serum phoenixin-20 and weight (r=-0.378; p<0.005), body mass index (r=-0.383; p<0.005), systolic blood pressure (r=-0.551; p<0.001), and diastolic blood pressure (r=-0.306; p<0.01). We used receiver operating characteristic curve analyses to compare the diagnosis value of Phoenixin-14 and Phoenixin-20 levels in hypertensive patients. We found that Phoenixin-14 value is an area under the curve of 0.87 (cutoff value 404.7 ng/L, sensitivity 92%, specificity 72%) and Phoenixin-20 value is an area under the curve of 0.83 (cutoff value 209.9 ng/L, sensitivity 86%, specificity 75%). Phoenixin-14 did nearly show equally compared to phoenixin-20 in predicting hypertension. CONCLUSION: Serum phoenixin-14 and phoenixin-20 may be related to the pathogenesis of hypertension. Our findings indicated that serum phoenixin-14 and phoenixin-20 may serve as a novel biomarker for the diagnosis of hypertension.